Research programme: cancer therapeutics - Novelix

Drug Profile

Research programme: cancer therapeutics - Novelix

Alternative Names: NVX-144; NVX-188

Latest Information Update: 04 Sep 2009

Price : $50

At a glance

  • Originator University of Southern California
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Integrin alphaVbeta3 antagonists; Interleukin 24 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 04 Sep 2009 Preclinical development is ongoing in USA
  • 19 Dec 2005 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top